Abstract
Galanthamine (1,2,3,4,6,7,7a,11c-Octahydro-9-2-methoxy-2-methylben-zofuro[4,3,2-efg][2]benzazocin-6-ol), mol wt 287.35, pKa 8.32, is a tertiary amine alkaloid, that has been isolated from plants of the amaryllidaceae family (Proskurnina et al., 1952; Uyeo et al., 1953). The chemical structure of these alkaloids resembles codeine and weak analgesic effects have been described in animals in vivo (Cozanitis et al., 1983). It penetrates the blood-brain-barrier (Wislicki, 1967; Bickel et al., 1991).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Atack JR, Perry EK, Bonham JR, Candy JM and Perry RH (1986): Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 47:263–277.
Bickel U, Thomsen T, Fischer JP, Weber W and Kewitz H (1991): Galanthamine: Pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology (In Press).
Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M and Kewitz H (1991): Pharmacokinetics of galanthamine in man and corresponding cholinesterase inhibition. Clin Pharm Ther (Submitted).
Holl G, Straschill M, Thomsen T, Fischer JP and Kewitz H (1991): Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials. EEG Journal (Submitted).
Mayrhofer O (1966): Clinical experiences with diallyl-nor-toxiferine and the curare antidote galanthamine. South Med J 59:1364–1368.
Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J and Jovovich V (1989): Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 39:50–58.
Nesterenko LN (1964): Influence exerted by galanthamine on the acetylcholinesterase activity of various regions of the brain. Farmakol Toksikol 28:413–414.
Pestel M (1961): Une nouvelle médication de la myasthenie et des dystrophies neuro-musculaires: La nivaline. Presse Med 69:182–183.
Proskurnina NF and Yakovleva J (1952): J Gen Chem U.S.S.R. 22:1899
Rainer M, Mark T and Haushofer A (1989): Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer’s type. In: Pharmacological interventions on central cholinergic mechanisms in senile dementia, Kewitz H, Thomsen T, Bickel U, eds. München: Zuckschwerdt, pp. 233–237.
Sherman KA and Messamore E (1988): Blood cholinesterase inhibition as a guide to the efficacy of putative therapies for Alzheimer’s dementia. Comparison of tacrine and physostigmine. In: Current Research in Alzheimer Therapy, Giacobini E and Becker R, eds. New York: Taylor and Francis, pp 73–86.
Stojanov EA (1965): Clinical experiences with the new curare antidote galanthamine (nivalin). In: European trends in Anaesthesiology. International Anaesthesiology Clinics. Mayrhofer O, ed. Boston: Brown & Co., pp. 675–685.
Sweeney JE, Höhmann CF, Moran TH and Coyle JT (1988): A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 31:141–147.
Sweeney JE, Puttfarcken PS and Coyle JT (1989): Galanthamine, an acetyl-cholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice. Pharmacol Biochem Behav 34:129–137.
Sweeney JE, Bachman ES and Coyle JT (1990): Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacol 102:191–200.
Thomsen T, Kewitz H and Pleul O (1988): Estimation of cholinesterase activity (EC 3.1.1.7; 3.1.1.8) in undiluted plasma and erythrocytes as a tool for measuring in vivo effects of reversible inhibitors. J Clin Chem Clin Biochem 26:469–75.
Thomsen T, Kewitz H and Pleul O (1989): A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors. Enzyme 42:219–224.
Thomsen T, Bickel U, Fischer JP and Kewitz H (1990a): Galanthamine hydrobromide in a long-term treatment of Alzheimer’s disease. Dementia 1:46–51.
Thomsen T and Kewitz H (1990b): Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 46:1553–1558.
Thomsen T, Bickel U, Fischer JP and Kewitz H (1990c): Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 39:603–605.
Thomsen T, Fischer JP, Bickel U, Kaden B and Kewitz H (1991): Inhibition of cholinesterases in vitro in human brain and erythrocytes by galanthamine. Naunyn-Schmiedeberg’s Arch Pharmacol 343 (Suppl.):R130.
Ueda M, Matsumura S, Kimoto S and Matsuda S (1962): Studies on the anticholinesterase and twitch potentiation activities of galanthamine. Jap J Pharmacol 12:111–119.
Uyeo S and Kobayashi S (1953): Pharm Bull Tokyo 1:139.
Vasilenko ET and Tonkopii VD (1974): Characteristics of galanthamine as a reversible inhibitor of cholinesterase. Biokhimiya 39:701–703.
Westra P, vanThiel MJS, Vermeer GA, Soeterbroek AM, Scaf AHJ and Claessens HA (1986): Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients. Br J Anaesth 58:1303–1307.
Wislicki L (1967): Nivalin (galanthamine hydrobromide), an additional decurarizing agent, some introductory observations. Br J Anaesth 39:963–968.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Thomsen, T., Kewitz, H., Bickel, U., Straschill, M., Holl, G. (1991). Preclinical and Clinical Studies with Galanthamine. In: Becker, R., Giacobini, E. (eds) Cholinergic Basis for Alzheimer Therapy. Advances in Alzheimer Disease Therapy. Birkhäuser, Boston, MA. https://doi.org/10.1007/978-1-4899-6738-1_35
Download citation
DOI: https://doi.org/10.1007/978-1-4899-6738-1_35
Publisher Name: Birkhäuser, Boston, MA
Print ISBN: 978-1-4899-6740-4
Online ISBN: 978-1-4899-6738-1
eBook Packages: Springer Book Archive